Is VRTX a Portfolio Must Have After Two FDA Nods Ahead of Q4 Earnings?
On Vertex's Q4 earnings call, investors will focus on management's comments about launch preparation for Alyftrek (vanza ...
Best Biotech Stocks To Consider – February 03rd
AbbVie, Vertex Pharmaceuticals, and Thermo Fisher Scientific are the three Biotech stocks to watch today, according to ...
stocknews4d
3 Genomic Stocks at the Forefront of Precision Medicine
Precision medicine is revolutionizing healthcare, and these genomic stocks are leading the way. Therefore, as this sector ...
Vertex Pharmaceuticals Unusual Options Activity
Financial giants have made a conspicuous bearish move on Vertex Pharmaceuticals. Our analysis of options history for Vertex ...
FDA approves first new non-opioid painkiller in decades, and it's from a MA company.
The U.S. Food and Drug Administration approved a new non-opioid pain medication developed by the Massachusetts-based company ...
stocknews9d
3 Biotech Stocks Revolutionizing Healthcare
Driven by rapid innovations and the integration of modern technologies, the biotech sector is experiencing robust growth.
American Association of Individual Investors9d
Which Is a Better Investment, Natera, Inc. or Vertex Pharmaceuticals Incorporated Stock?
Learn more about whether Natera, Inc. or Vertex Pharmaceuticals Incorporated is a better investment based on AAII's A+ ...
Pharmaceutical Technology17d
Suzetrigine by Vertex Pharmaceuticals for Diabetic Peripheral Neuropathy: Likelihood of Approval
The company’s product portfolio includes Trikafta, Symdeko/Symkevi, Orkambi (ivacaftor/lumacaftor), and Kalydeco (ivacaftor) for treating cystic fibrosis. Through its research and development efforts, ...
Benzinga.com29d
Forecasting The Future: 23 Analyst Projections For Vertex Pharmaceuticals
Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through ...